Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

Phase 1

Terminated

Conditions: Relapsed/Refractory Large B-cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Axicabtagene Ciloleucel
Biological: Utomilumab

First Posted Date: 2018-10-12

Last Posted Date: 2024-06-28

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 15

Registration Number: NCT03704298

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Phase 2

Withdrawn

Conditions: Neoplasms

Interventions: Drug: GSK3377794
Drug: Pembrolizumab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-10-05

Last Posted Date: 2019-10-29

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT03697824

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Phase 1

Recruiting

Conditions: Lymphoma
Lymphoma, B-Cell
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases

Interventions: Biological: iC9-CAR19 T cells
Drug: Bendamustine
Drug: Fludarabine
Drug: AP1903
Drug: Cyclophosphamide

First Posted Date: 2018-10-05

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT03696784

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Fludarabine
Radiation: Total Marrow Irradiation (TMI)

First Posted Date: 2018-10-04

Last Posted Date: 2022-03-09

Lead Sponsor: Naoyuki G. Saito, M.D., Ph.D.

Target Recruit Count: 6

Registration Number: NCT03696537

Locations: 🇺🇸
Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia, Adult
Acute Lymphoblastic Leukemia, Pediatric
Chronic Lymphocytic Leukemia
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma

Interventions: Biological: CD19.CAR T Cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-09-18

Last Posted Date: 2024-07-29

Lead Sponsor: University Hospital Heidelberg

Target Recruit Count: 68

Registration Number: NCT03676504

Locations: 🇩🇪
University Hospital Heidelberg, Heidelberg, Germany

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1

Suspended

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Refractory Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia in Remission
Recurrent Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia in Remission
Myelodysplastic Syndrome With Excess Blasts
Chronic Myelomonocytic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Bone Marrow Transplantation
Drug: Mycophenolate Mofetil
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Fludarabine Phosphate
Drug: Tacrolimus
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Biospecimen Collection

First Posted Date: 2018-09-14

Last Posted Date: 2024-05-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03670966

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Phase 1

Recruiting

Conditions: B-cell Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma

Interventions: Biological: Azer-cel
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: IL-2
Drug: Bendamustine

First Posted Date: 2018-09-11

Last Posted Date: 2024-12-16

Lead Sponsor: Imugene Limited

Target Recruit Count: 129

Registration Number: NCT03666000

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States

and more 18 locations

Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Selinexor
Drug: fludarabine
Drug: idarubicin
Drug: cytarabine
Drug: G-CSF

First Posted Date: 2018-09-07

Last Posted Date: 2020-05-20

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 16

Registration Number: NCT03661515

Locations: 🇪🇸
Hospital San Pedro de Alcántara,, Cáceres, Spain
🇪🇸
Hospital la Fe, Valencia, Spain
🇪🇸
Hospital Germans Tries i Pujol, Badalona, Badalona, Spain

and more 1 locations

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1

Recruiting

Conditions: Recurrence Tumor
Metastatic Cancer
Solid Tumor

Interventions: Biological: TIL
Drug: Aldesleukin
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2018-09-05

Last Posted Date: 2024-08-13

Lead Sponsor: Tongji Hospital

Target Recruit Count: 40

Registration Number: NCT03658785

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Phase 1

Recruiting

Conditions: Diamond-blackfan Anemia
Sickle Cell Anemia
Beta-thalassemia Major

Interventions: Biological: CD3/CD19 depleted leukocytes
Biological: CD45RA depleted leukocytes
Drug: Hydroxyurea
Drug: Rituximab
Drug: Alemtuzumab
Drug: Fludarabine
Drug: Thiotepa

First Posted Date: 2018-08-31

Last Posted Date: 2024-08-09

Lead Sponsor: Paul Szabolcs

Target Recruit Count: 5

Registration Number: NCT03653338

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy